The study suggested that QTHX treats NASH in rats by activating the SCOS1/NF-κB/TLR4 pathway, suggesting QTHX could be further developed as a potential liver-protecting agent. Here, NFKB1 is linked to metabolic dysfunction-associated steatohepatitis.